The Biotech Rebuild: Finding Alpha After the Drawdown with Chris Clark | #606

Episode Summary

Executive Summary: Meb Faber and biotech veteran Chris Clark argue that biotech is a misunderstood, probabilistic asset class now emerging from a multi-year bear market caused by rising rates, stalled M&A, and funding stress. Clark frames biotech as a long-duration, capital-intensive game of skill where cash runway, valuation to cash, and acquisition optionality matter far more than traditional quant factors.

Main Topics: Biotech as an asset class and how it differs from typical equities (Priority: 5/5): Clark defines biotech/pharma as a distinct, highly diverse sector focused on moving scientific ideas through animal, human, regulatory, and commercial stages. He emphasizes that traditional stock metrics often fail because biotech companies are built around long development cycles, binary trial outcomes, and capital raises rather than earnings growth. The biotech conveyor belt and why the market froze (Priority: 5/5): The conversation centers on the 'conveyor belt' from private biotech funding to IPOs to eventual M&A by big pharma. Clark argues the pipeline jammed because downstream M&A stopped, causing capital to back up and the public/private ecosystem to seize up for years. Investing framework: poker, EV-to-cash, and cash runway (Priority: 5/5): Clark rejects the idea that biotech is a lottery ticket, instead treating it as expected value analysis: probability of success, payout if successful, and loss if not. He highlights EV-to-cash and cash runway as the most useful screens, because other quant factors are often irrelevant or misleading. Why biotech underperformed and why the cycle may be turning (Priority: 5/5): Clark says the science did not deteriorate; the main driver of the sector’s weak performance was macro: rising rates, liquidity withdrawal, and M&A shutdown after the pandemic boom. He believes healing is underway as M&A reopens, capital markets normalize, and valuations remain attractive. Behavioral biases, benchmark construction, and underownership (Priority: 4/5): A major theme is how generalist managers and consultants avoid biotech due to drawdown fear, yet that avoidance creates unintended benchmark risk and missed upside. Clark argues that because biotech is such a large part of healthcare benchmarks, being underweight it often means hidden overexposure elsewhere. Public vs. private biotech and the role of long-duration capital (Priority: 4/5): Clark says public and private biotech are part of the same continuum, with IPOs functioning as an 'on-ramp' rather than an exit. He argues the market needs committed long-duration capital, not short-horizon IRR-driven capital, to fund the gap between discovery and commercialization. AI, regulation, and future subsectors (Priority: 4/5): AI is presented as an accelerant for drug discovery, patient selection, and trial design—not a replacement for clinical trials. Regulatory issues such as the IRA and most-favored-nation pricing are discussed as key variables affecting valuation, M&A, and launch strategy, while Clark favors single-product, capital-efficient stories over platform science projects.

Key Arguments: Biotech is not a lottery ticket; it is a game of skill where investors can estimate expected value using payout, probability, and downside. Traditional quant screens largely fail in biotech because many factors are irrelevant and others are counterproductive; EV-to-cash and runway matter most. The biotech bear market was driven primarily by macro conditions—especially higher rates and stalled M&A—not by worsening science. Well-funded biotech companies can be defensive in the near term because their trial outcomes are less sensitive to macro shocks once capitalized. The sector’s major issue is not drug development alone but exit optionality: if M&A is shut, the economic model breaks down. Generalist investors and consultants often avoid biotech for perceived risk, but that creates benchmark and tracking-error problems rather than true safety. Biotech is currently attractive because valuations are depressed, M&A is returning, and capital markets are reopening, creating a potential generational opportunity. Public and private biotech are two parts of the same capital continuum; IPOs in biotech are entrances for new capital, not exits like in tech. Long-duration evergreen capital is better suited to biotech than short-IRR crossover or opportunistic funds. AI will help most in lead generation, patient segmentation, and trial optimization, but it cannot eliminate the need for clinical validation.

Data Points: Cropland loss: 4.8 acres per minute - Used in the sponsor intro to illustrate farmland scarcity and the case for farmland investing. AcreTrader minimum investment: $15,000 - Sponsor mention describing passive access to farmland. Biotech product development time: 8 to 15 years - Clark described the time from hypothesis to market approval and commercialization. Cost to bring a product to market: $800 million to $1 billion - Direct development cost estimate, before accounting for failures. Cost including failed programs: ~$2 billion - Clark noted survivor bias makes the true industry cost much higher. Typical phase success chain: ~10% phase 1, ~40% phase 2, ~75% phase 3, ~95% filing approval - Clark gave approximate historical success rates to illustrate compounding attrition. Cash runway at deal/tape sweet spot historically: 18 months - Former norm for biotech balance-sheet management before the post-pandemic shift. Post-pandemic cash runway norm: 1 to 2+ years - He said the market’s expectations shifted upward during the funding squeeze. Share price reaction if cash < 1 year: -40% to -50% - Positive data could still be punished if the company lacked runway. Typical stock drawdown in a year: 50% - Clark contrasted ordinary equities with biotech drawdowns. Typical biotech annual drawdown: 60% - He used this to show biotech is only modestly more volatile than small-cap growth generally. Non-biopharma annual drawdown: 48.5% - Clark said removing biopharma from the sector barely changed the drawdown profile. Pharma share of US healthcare spend: 9% - Used to argue drug pricing debates overstate pharmaceuticals’ share of total healthcare costs. Healthcare admin inefficiency estimate: 9% of healthcare spend - Clark said hospital administrative waste alone could cover drug costs in theory. US share of drug value historically vs today: 50% historically; 80% today - Discussed under global pricing pressure and MFN pricing debates. Biopharma weight in benchmark at pandemic peak: 24% - Used to show why underweight positions in biotech created large tracking error. Generalist underweight vs benchmark: 20% underweight; at peak, 50% underweight - Clark cited Jefferies/Steve DeSanctis slide showing chronic underownership. Small-cap growth biotech current weight: ~10% to 12% - Clark said the benchmark weight has fallen from prior peaks but is rebounding. Historical small-cap growth biotech peak weight: ~24% - Referenced as the high-water mark during the 2020-2021 period. Market cap bands for biotech names mentioned: >$100M to <$5B - Clark referenced roughly 300-500 names in this range depending on classification. Biotech survival index concern: 60% of companies had two or fewer years of cash - He cited EY data that shocked many observers but matched the funding reality. Forward return from EV-to-cash bottom zone: ~17% compounded - Brian Jacobs layered forward returns on the EV-to-cash screen. Example acquisition multiple: 5x peak sales - Clark said an Eli Lilly CFO used this as a practical acquisition framework for small molecules. Pharmasset acquisition value: $11 billion - Example of a landmark biotech acquisition after hepatitis C data. Pharmasset outcome: $14 billion revenue in first full year - Clark described how the acquired asset quickly became hugely commercial. MoonLake drawdown example: ~90%+ - He cited a recent biotech blow-up where the stock traded toward cash after mixed trial data.

Pivotal Quotes: "Biotech is, in my opinion, the most diverse industry that's out there." — Chris Clark: Clark explaining why biotech should be treated as its own sector rather than lumped into generic healthcare. "I think of them more like poker. This is a game of skill, not a game of chance." — Chris Clark: His core framework for valuing biotech investments as expected value rather than lottery tickets. "The IPO is an entrance. It's not an exit. It's an on-ramp." — Chris Clark: Clark distinguishing biotech IPOs from tech IPOs and describing how public capital feeds the same development pipeline.

Implications: Biotech may be at an inflection point: valuations are depressed, capital markets are reopening, and M&A is returning. Investors with long duration and specialist knowledge may find asymmetric opportunities, while generalists may continue to misprice the space.